| scholarly article | Q13442814 |
| P50 | author | Michele Baccarani | Q66370907 |
| Emanuela Ottaviani | Q66382511 | ||
| Raimondo De Cristofaro | Q42054575 | ||
| Sergio Rutella | Q42054583 | ||
| P2093 | author name string | Antonio Curti | |
| Roberto M Lemoli | |||
| Cecilia Evangelisti | |||
| Darina Ocadlikova | |||
| Valentina Salvestrini | |||
| Chiara Onofri | |||
| Michela Aluigi | |||
| Sara Trabanelli | |||
| P2860 | cites work | Tolerance, DCs and tryptophan: much ado about IDO | Q28203295 |
| Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase | Q28204166 | ||
| Interleukin-11 induces Th2 polarization of human CD4(+) T cells | Q57007772 | ||
| Thymosin 1 activates dendritic cell tryptophan catabolism and establishes a regulatory environment for balance of inflammation and tolerance | Q58855391 | ||
| Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogenous leukemia | Q73063879 | ||
| Stimulation of autologous proliferative and cytotoxic T-cell responses by "leukemic dendritic cells" derived from blast cells in acute myeloid leukemia | Q73785023 | ||
| Circulating blood dendritic cells from myeloid leukemia patients display quantitative and cytogenetic abnormalities as well as functional impairment | Q77337172 | ||
| Human acute myeloblastic leukemia cells differentiate in vitro into mature dendritic cells and induce the differentiation of cytotoxic T cells against autologous leukemias | Q78162686 | ||
| CD34(+) acute myeloid and lymphoid leukemic blasts can be induced to differentiate into dendritic cells | Q78225346 | ||
| Dendritic cells have the option to express IDO-mediated suppression or not | Q81474897 | ||
| Cancer immunoediting: from immunosurveillance to tumor escape | Q28212251 | ||
| Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival | Q29547865 | ||
| IDO expression by dendritic cells: tolerance and tryptophan catabolism | Q29614752 | ||
| Tryptophan catabolism and T-cell tolerance: immunosuppression by starvation? | Q33740214 | ||
| Malignant counterpart of myeloid dendritic cell (DC) belonging to acute myelogenous leukemia (AML) exhibits a dichotomous immunoregulatory potential | Q34170214 | ||
| Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. | Q34515741 | ||
| Increase of regulatory T cells in the peripheral blood of cancer patients. | Q34531138 | ||
| The indoleamine 2,3-dioxygenase pathway is essential for human plasmacytoid dendritic cell-induced adaptive T regulatory cell generation | Q34657284 | ||
| Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. | Q35561038 | ||
| Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma | Q35849633 | ||
| Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase | Q35925641 | ||
| Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. | Q36376561 | ||
| Regulatory T cells, tumour immunity and immunotherapy | Q36430144 | ||
| Feasibility of clinical dendritic cell vaccination in acute myeloid leukemia | Q36571706 | ||
| Indoleamine 2,3-dioxygenase-expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells. | Q37268984 | ||
| The role of indoleamine 2,3-dioxygenase in the induction of immune tolerance: focus on hematology | Q37331219 | ||
| Relationship between interferon-gamma, indoleamine 2,3-dioxygenase, and tryptophan catabolism | Q37349845 | ||
| Toward the identification of a tolerogenic signature in IDO-competent dendritic cells. | Q38317862 | ||
| Indoleamine 2,3-dioxygenase activity of acute myeloid leukemia cells can be measured from patients' sera by HPLC and is inducible by IFN-gamma. | Q40068974 | ||
| Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25- into CD25+ T regulatory cells | Q40197317 | ||
| More rapid method for simultaneous measurement of tryptophan and kynurenine by HPLC. | Q43893230 | ||
| CTLA-4-Ig regulates tryptophan catabolism in vivo. | Q44170968 | ||
| Functional plasticity of dendritic cell subsets as mediated by CD40 versus B7 activation | Q44556007 | ||
| Modulation of tryptophan catabolism by regulatory T cells. | Q44632333 | ||
| Regulation of human auto- and alloreactive T cells by indoleamine 2,3-dioxygenase (IDO)-producing dendritic cells: too much ado about IDO? | Q45168864 | ||
| Interferon-gamma-triggered indoleamine 2,3-dioxygenase competence in human monocyte-derived dendritic cells induces regulatory activity in allogeneic T cells. | Q45922663 | ||
| High INDO (indoleamine 2,3-dioxygenase) mRNA level in blasts of acute myeloid leukemic patients predicts poor clinical outcome | Q46218678 | ||
| Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine | Q46508260 | ||
| A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. | Q47953114 | ||
| Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6. | Q51045048 | ||
| In vivo peripheral expansion of naive CD4+CD25high FoxP3+ regulatory T cells in patients with multiple myeloma. | Q51985543 | ||
| CD4+CD25high Foxp3+ regulatory T cells in myelodysplastic syndrome (MDS). | Q53239013 | ||
| Acute myeloid leukemia cells constitutively express the immunoregulatory enzyme indoleamine 2,3-dioxygenase. | Q54703524 | ||
| The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells | Q56902123 | ||
| Increased population of CD4(+)CD25(high), regulatory T cells with their higher apoptotic and proliferating status in peripheral blood of acute myeloid leukemia patients | Q56902500 | ||
| Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma | Q56903494 | ||
| Interleukin-12 production by leukemia-derived dendritic cells counteracts the inhibitory effect of leukemic microenvironment on T cells | Q56999120 | ||
| P433 | issue | 12 | |
| P921 | main subject | dendritic cell | Q506253 |
| leukemia | Q29496 | ||
| P304 | page(s) | 2022-2030 | |
| P577 | publication date | 2010-08-26 | |
| P1433 | published in | Haematologica | Q5638209 |
| P1476 | title | Indoleamine 2,3-dioxygenase-expressing leukemic dendritic cells impair a leukemia-specific immune response by inducing potent T regulatory cells | |
| P478 | volume | 95 |
| Q99571008 | A Screening of Antineoplastic Drugs for Acute Myeloid Leukemia Reveals Contrasting Immunogenic Effects of Etoposide and Fludarabine |
| Q47194065 | ATP Release from Chemotherapy-Treated Dying Leukemia Cells Elicits an Immune Suppressive Effect by Increasing Regulatory T Cells and Tolerogenic Dendritic Cells. |
| Q57491404 | Acute Myeloid Leukemia Cells Express ICOS Ligand to Promote the Expansion of Regulatory T Cells |
| Q92990818 | Can Dendritic Cell Vaccination Prevent Leukemia Relapse? |
| Q39299639 | Complex evaluation of human monocyte-derived dendritic cells for cancer immunotherapy |
| Q38068967 | Current strategies in immunotherapy for acute myeloid leukemia |
| Q33403052 | Decreased expression of indoleamine 2,3-dioxygenase 1 in dendritic cells contributes to impaired regulatory T cell development in immune thrombocytopenia. |
| Q91613560 | Dendritic Cell-Based Immunotherapy of Acute Myeloid Leukemia |
| Q37420778 | Dendritic cell-based immunotherapy for myeloid leukemias. |
| Q38110935 | Dendritic cells in myelodysplastic syndromes: from pathogenesis to immunotherapy. |
| Q35853686 | IL-17/IL-10 double-producing T cells: new link between infections, immunosuppression and acute myeloid leukemia |
| Q36478891 | Immunologic consequences of chemotherapy for acute myeloid leukemia |
| Q28654567 | Immunological Relevance of the Coevolution of IDO1 and AHR |
| Q38171574 | Immunotherapy in acute myeloid leukemia |
| Q42572959 | Increased CD200 expression in acute myeloid leukemia is linked with an increased frequency of FoxP3+ regulatory T cells. |
| Q55249105 | Increased Regulatory T Cells in Peripheral Blood of Acute Myeloid Leukemia Patients Rely on Tumor Necrosis Factor (TNF)-α-TNF Receptor-2 Pathway. |
| Q36526999 | Indoleamine 2,3-dioxygenase 1 (IDO1) activity correlates with immune system abnormalities in multiple myeloma. |
| Q33688517 | Indoleamine 2,3-dioxygenase 1 (IDO1) activity in leukemia blasts correlates with poor outcome in childhood acute myeloid leukemia. |
| Q51097416 | Indoleamine 2,3-dioxygenase in psoriasis: a defective mechanism. |
| Q34427452 | Influence of tryptophan contained in 1-Methyl-Tryptophan on antimicrobial and immunoregulatory functions of indoleamine 2,3-dioxygenase |
| Q26746104 | Mesenchymal Stem and Progenitor Cells in Normal and Dysplastic Hematopoiesis-Masters of Survival and Clonality? |
| Q39045520 | Modulation of cancer-specific immune responses by amino acid degrading enzymes |
| Q26770391 | Novel immunotherapeutic approaches for the treatment of acute leukemia (myeloid and lymphoblastic) |
| Q60301541 | Overexpression of indoleamine 2,3-dioxygenase correlates with regulatory T cell phenotype in acute myeloid leukemia patients with normal karyotype |
| Q42256888 | PGE2-induced IDO1 inhibits the capacity of fully mature DCs to elicit an in vitro antileukemic immune response |
| Q28392626 | Pathological mobilization and activities of dendritic cells in tumor-bearing hosts: challenges and opportunities for immunotherapy of cancer |
| Q35553553 | Regulatory T cells in acute myelogenous leukemia: is it time for immunomodulation? |
| Q42101420 | The Human Mesenchymal Stromal Cell-Derived Osteocyte Capacity to Modulate Dendritic Cell Functions Is Strictly Dependent on the Culture System |
| Q58599938 | The metabolite BH4 controls T cell proliferation in autoimmunity and cancer |
| Q38250205 | The role of the immunosuppressive microenvironment in acute myeloid leukemia development and treatment |
| Q39150753 | Up-regulated expression of indoleamine 2,3-dioxygenase 1 in non-Hodgkin lymphoma correlates with increased regulatory T-cell infiltration |
| Q46952293 | Upregulation of CD200 is associated with Foxp3+ regulatory T cell expansion and disease progression in acute myeloid leukemia |
Search more.